Valuation : Wockhardt Limited

Market Cap 319B 3.34B 2.87B 2.68B 2.46B 4.63B 4.64B 31.77B 12.42B 161B 12.53B 12.26B 532B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 334B 3.5B 3B 2.81B 2.58B 4.85B 4.87B 33.31B 13.02B 169B 13.14B 12.86B 558B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day+0.77%
1 week+8.27%
Current month+0.89%
1 month+6.00%
3 months+16.29%
6 months+44.99%
Current year+36.71%
1 week 1,825
Extreme 1825
2,045
1 month 1,814.4
Extreme 1814.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%+8.27%+34.48%+759.24% 3.34B
+0.35%+1.05%+19.98%+71.89% 48.07B
-0.08%+0.95%+54.19%+121.68% 40.17B
+0.15%+7.83%+20.56%+87.77% 12.42B
+0.25%+0.11%-9.89%+15.84% 12.01B
+0.19%0.00%+30.98%+150.00% 9.38B
-0.82%+2.87%+24.06%+44.81% 7.78B
+0.04%-0.12%+52.32%-11.95% 7.24B
+2.24%+11.95%+28.93%+227.84% 7.27B
+0.95%-8.22%-39.88%+16.67% 5.33B
Average +0.40%+1.35%+21.57%+148.38% 15.3B
Weighted average by Cap. +0.25%+0.16%+27.73%+101.77%

Financials

2025 2026
Net sales 30.35B 318M 273M 255M 234M 441M 442M 3.02B 1.18B 15.3B 1.19B 1.17B 50.62B 34.62B 362M 311M 291M 267M 503M 504M 3.45B 1.35B 17.45B 1.36B 1.33B 57.75B
Net income -470M -4.92M -4.22M -3.95M -3.62M -6.82M -6.84M -46.83M -18.31M -237M -18.48M -18.08M -784M 2.13B 22.3M 19.14M 17.92M 16.41M 30.92M 31M 212M 82.97M 1.07B 83.73M 81.92M 3.55B
Net Debt 14.33B 150M 129M 121M 110M 208M 209M 1.43B 558M 7.22B 563M 551M 23.9B 15.53B 163M 140M 131M 120M 225M 226M 1.55B 605M 7.83B 610M 597M 25.9B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-28 1,977.10 +0.77% 1,581,060
26-08-27 ₹1,962.00 +4.25% 1,210,241
26-08-26 ₹1,882.10 -0.92% 310,259
26-08-25 ₹1,899.60 -0.07% 241,579
26-08-24 ₹1,901.00 +0.78% 306,988
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock